Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Researchers Urge Ability of Two Non-psychoactive Cannabis Molecules; Could Soon Replace Opioids & Aspirins

Common chronic pain suffered by many individuals, such as pain from arthritis, is due to inflammation and the aggravation associated with the inflammation. Aspirins can reduce inflammation, while opioid pain relievers are often prescribed to help to reduce the pain experienced by the body. Even though opioids are effective and can sometimes entirely eliminate the pain experienced, it does not stop the pain at the source. Opioids instead inhibit nerve cell receptors in specific locations within the body and effectively stop the pain signal from recognition in the brain.

Two cannabis molecules with the ability to take the spotlight away from opioids and aspirins, cannflavin A and cannflavin B, are non-psychoactive, able to reduce inflammation at the source, and do not share the addictive qualities that are found in opioids. It is estimated by the National Institute on Drug Abuse that more than 130 people die from opioid overdoses in the United States on a daily basis.

Tariq Akhtar, a professor at the department of molecular and cellular biology at the University of Guelph in Ontario, Canada, stated: “There’s clearly a need to develop alternatives for relief of acute and chronic pain that go beyond opioids. Our objective was to better understand how these [cannflavin] molecules are made, which is a relatively straightforward exercise these days.”

Technology has allowed for the professors who research flavonoids at the University of Guelph, like Prof. Akhtar and Prof. Steven Rothstein, to soon engineer large quantities of the two unique cannabis cannflavins. This is a big leap for the cannflavin’s feasibility as a potential new painkiller due to the fact that their natural presence in cannabis is too low to selectively breed and engineer strains with larger quantities. The university’s researchers are even now teamed up with the cannabis company Anahit International Corp. in order to discover a new way to manufacture large quantities of flavonoids like cannflavin A and cannflavin B.

Darren Carrigan, Chief Operating Officer of Anahit International Corp., stated: “Anahit looks forward to working closely with University of Guelph researchers to develop effective and safe anti-inflammatory medicines from cannabis phytochemicals that would provide an alternative to nonsteroidal anti-inflammatory drugs.”

Researchers Urge Ability of Two Non-psychoactive Cannabis Molecules; Could Soon Replace Opioids & Aspirins


About Cannin: Cannabis and Hemp Investment Experts

Market analysts expect the cannabis and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in cannabis and hemp stocks is now! Are you looking to buy stock in hemp companies or cannabis companies? Interested in emerging penny pot stock companies? Looking for the best Canadian pot company to invest in? Cannin is your trusted resource for information about Cannabis and Hemp stock investment opportunities. Our global team of experts evaluates emerging cannabis stock investing companies. We aggregate hundreds of hours of research and distill it down to make it easy for our investors to understand. We provide tips on the best cannabis and hemp stock investments for 2020. We provide the latest hemp investment news and analysis. Visit our site for cannabis investing news and featured companies, sign up for the free Cannin Chronicle or get a free trial of our smart cannabis and hemp stock algorithm to take the guesswork out of profiting from this exciting industry. Predict the price of cannabis and hemp stocks hours in advance with our machine learning algorithm. Is it too late to invest in marijuana? No! This is the perfect time.

Profit from the best Cannabis and Hemp stocks – we’ll show you how at cannin.com